Clinical trials
for patients

The primary objective of this study is to determine whether survodutide can reduce urinary protein levels in people with overweight who already have protein loss in their urine. This could help reduce the risk of long-term kidney damage.

The purpose of this study is to evaluate the safety and efficacy of each of the three study drugs (Fx, Bv, or Rz) in reducing kidney cell damage, decreasing the amount of protein that leaks into the urine, and improving symptoms, compared with placebo (a dummy treatment containing no active drug).

This study is open to adults with advanced or metastatic solid tumors, such as non-small cell lung cancer, head and neck squamous cell carcinoma, triple-negative breast cancer, esophageal squamous cell carcinoma, bladder cancer, vulvar cancer, and cervical cancer. Patients may participate if no standard treatment options are available to them and they have a measurable lesion outside the central nervous system. The aim of this study is to determine how well BI 3822971 is tolerated by people with...

The purpose of this research study is to evaluate the safety and efficacy of an investigational drug called mivelsiran (ALN-APP). This drug has not been approved by the health authorities in your country for use outside this research study. The study drug will be evaluated to determine the effects of mivelsiran in people with early-stage Down syndrome-associated Alzheimer’s disease (DS-AD). The study aims to determine: The effects of mivelsiran on the brain that can be observed using di...

This study is designed to collect long-term safety data and provide uninterrupted study treatment to participants with solid tumors who continue to benefit from adagrasib in an eligible clinical trial (parent study).

The aim of this study is to gather further information on how cilta-cel works and its safety in the treatment of patients with multiple myeloma, a type of cancer. The study will include different groups of patients, referred to as cohorts.

This study is designed to help determine whether the study drug pumitamig is effective in treating hepatocellular carcinoma (HCC), a type of liver cancer that is advanced or cannot be removed by surgery (referred to as unresectable).

The aim of this study is to determine the safety and efficacy (how well the study drugs work) of PVEK in combination with venetoclax (VEN) and azacitidine (AZA) in adult patients with newly diagnosed acute myeloid leukemia (AML) who are unable to receive intensive chemotherapy.

This research study evaluates ABP 938 8 mg compared with commercially available aflibercept (Eylea® HD). Its aim is to determine whether the efficacy (how well the study drug injection works), safety, and immunogenicity (the ability to trigger a response in the body to the study drug injection through the development of antibodies, a type of protein) of ABP 938 8 mg are similar to those of aflibercept (Eylea® HD) in the overall study population.

The purpose of this trial is to continue evaluating whether the investigational drug afimkibart, when administered over a longer period, is safe and effective for moderate-to-severe atopic dermatitis, and to determine the long-term effects, both positive and negative, of afimkibart on atopic dermatitis. You are being asked to participate in this trial because you have moderate-to-severe atopic dermatitis, participated in study CS45570, and responded to treatment with afimkibart.

The objective of this study is to determine whether CPV-104 (the study drug) is safe for use in people (safety), how manageable its side effects are (tolerability), the blood concentrations of CPV-104 and factor H (an important protein in the human body involved in the immune system) (pharmacokinetics), and whether CPV-104 triggers an immune response against foreign substances (immunogenicity).

The objective of this study is to determine whether esketamine is effective in treating adolescents aged 12 to 17 with major depressive disorder who are at imminent risk of suicide. The safety of esketamine in this population will also be evaluated.

This clinical trial is being conducted for research purposes. The study drug VER-01 is being investigated in patients with chronic nonspecific low back pain. The trial includes patients who require treatment for chronic low back pain for whom non-opioid analgesics are not appropriate because of contraindications, provide insufficient pain relief, or are not tolerated.

The objective of this study is to determine whether combination therapies with the study drugs—that is, ASP3082 and docetaxel, pembrolizumab, or a platinum-based chemotherapy regimen (cisplatin or carboplatin) and pemetrexed, with or without pembrolizumab—are safe and effective for treating people with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring a KRAS G12D mutation.

The objective of this trial is to determine how well a new investigational drug called visugromab (also known as CTL-002) works and whether it is safe when used in combination with nivolumab and lenvatinib.

The objective of this study is to collect data on the safety of the investigational study medication and to determine how well it works in treating grass pollen allergy.

The primary objective is to evaluate the safety and tolerability of the study drug.

The purpose of the study is to evaluate progression-free survival (PFS) with casdatifan versus placebo, when both are administered in combination with cabozantinib, in adult patients with confirmed advanced or metastatic clear cell renal cell carcinoma who experienced disease progression during or after prior anti-PD-1 or anti-PD-L1 immunotherapy.